about
A combination of molecular markers and clinical features improve the classification of pancreatic cysts.Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers.Alcohol activates the hedgehog pathway and induces related procarcinogenic processes in the alcohol-preferring rat model of hepatocarcinogenesis.Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancerThe effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.Cyclooxygenase-2 expression in hamster and human pancreatic neoplasiaAlcohol induces liver neoplasia in a novel alcohol-preferring rat modelThe proteome of normal pancreatic juiceThe role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy.Natural and synthetic α,β-unsaturated carbonyls for NF-κB inhibition.Factors influencing the cytotoxicity of α-methylene-γ-hydroxy esters against pancreatic cancer.Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.Synthetic α-(aminomethyl)-γ-butyrolactones and their anti-pancreatic cancer activities.The first synthesis of a borylated α-methylene-γ-butyrolactone.Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.Regulation of the Raf-1 kinase domain by phosphorylation and 14-3-3 association.Tailored α-methylene-γ-butyrolactones and their effects on growth suppression in pancreatic carcinoma cells.Ethanol-TGFalpha-MEK signaling promotes growth of human hepatocellular carcinomaResistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems.Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts.Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.Sulindac prevents carcinogen-induced intrahepatic cholangiocarcinoma formation in vivo.Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts.PGE(2) in pancreatic cyst fluid helps differentiate IPMN from MCN and predict IPMN dysplasia.Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice.Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer.Transforming growth factor α levels in pancreatic fluid.Prostaglandin E2: A Pancreatic Fluid Biomarker of Intraductal Papillary Mucinous Neoplasm Dysplasia.
P50
Q30724746-F670216D-95D3-4733-A2B9-34713FEDE838Q31856389-14A3CA7A-B2F9-4D49-BFA6-212BEC8374BEQ33735346-7373DCE2-EE2B-4E3A-8CD8-98D0B236131FQ33745654-625CB87D-1CD7-4CEC-895E-EAE544004DB8Q34556749-6825D795-F8E5-455D-A854-8448C7244B7BQ34670483-2E1A8BC3-D3F6-4D92-9CFA-65FCEE8BC14CQ35081944-74B937F8-E557-4122-B04A-61F97BFA6ED7Q35082208-15C87EE0-B663-4BE7-8078-F351D52A5B2EQ35478720-E9794C8C-AF67-4D15-AE81-012A88114A60Q35784518-FA7AB15F-A95C-485B-8329-BF17A9BA5C67Q37117530-DD868DCF-D56F-4FB8-9510-10355154093BQ37855873-9C871D98-8093-4FAF-A09A-F9B720FB54C2Q38844420-5FCE5481-8FF6-458D-854D-7DDA4AE72B7BQ38849474-F7347567-32CC-44EB-8C25-C36C5672931AQ39068312-763AA8CA-CD16-417B-9ABB-8C2776BDEA39Q39160708-673B7099-CDD2-4F6F-B49F-FE41EAC2C8BFQ39344030-31137F07-97CE-41CC-BB73-610937630AC9Q39426606-42859468-59C9-4EA2-ABE3-91CADA341682Q39649007-F3546FD2-25EF-4AD1-9A4E-1D18A5E793B8Q39868384-33D79F93-8D80-452A-B9C3-67F8742C9273Q39877518-3D395F59-1585-462B-8F65-30A5FE906E24Q39983941-9B071D4B-2F5F-47C5-A521-A9C50E275272Q40056869-00C52B52-5371-4A15-A039-F05549BED1F2Q40125582-C6165034-BCEC-4A93-90E4-8FD61F896923Q40241432-D598F1B7-E8BB-4CE4-90A5-274766B63877Q40267171-262D6143-5B65-461D-B78B-DC02E1A869E5Q40583889-F641CECC-4186-4ECD-BD70-97ADC5A83AC3Q40623407-1CCE0F72-591C-4163-BFD0-7A99FFF2D32CQ42521987-4D77D6A6-FCE2-4153-9F56-716FFAD57FFBQ43180945-45DCF3D2-ECB9-4EB7-AC66-6877837ABECEQ43472511-30BE0160-F1A3-443A-BF81-EAF7992D52BFQ44374245-2614955E-C736-4C42-8D49-B0B1073C32CDQ45947638-12C86F9E-621E-4F97-AF72-EAFAE425C413Q46348567-CEC0FEB8-88BD-440F-8F66-311960FD0BABQ46867228-BD95A052-9E3C-4B9A-88FD-16CF6E6149FBQ46890528-CE2B8DD5-6DA2-4F63-A0B4-0D64CB8E15D8Q46911481-9F575FB7-A3C4-498C-8895-B4F0DA167EF5Q46940365-6AD8D950-BFDA-4933-95CD-9253CCE60AFCQ51049048-8CB7EA10-8B7D-4FA3-936D-24B8541FC194Q51820838-C321B6E1-9DA2-40D8-B3BB-BB94A5FF237D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michele T Yip-Schneider
@af
Michele T Yip-Schneider
@an
Michele T Yip-Schneider
@ast
Michele T Yip-Schneider
@bar
Michele T Yip-Schneider
@br
Michele T Yip-Schneider
@ca
Michele T Yip-Schneider
@co
Michele T Yip-Schneider
@cs
Michele T Yip-Schneider
@cy
Michele T Yip-Schneider
@da
type
label
Michele T Yip-Schneider
@af
Michele T Yip-Schneider
@an
Michele T Yip-Schneider
@ast
Michele T Yip-Schneider
@bar
Michele T Yip-Schneider
@br
Michele T Yip-Schneider
@ca
Michele T Yip-Schneider
@co
Michele T Yip-Schneider
@cs
Michele T Yip-Schneider
@cy
Michele T Yip-Schneider
@da
prefLabel
Michele T Yip-Schneider
@af
Michele T Yip-Schneider
@an
Michele T Yip-Schneider
@ast
Michele T Yip-Schneider
@bar
Michele T Yip-Schneider
@br
Michele T Yip-Schneider
@ca
Michele T Yip-Schneider
@co
Michele T Yip-Schneider
@cs
Michele T Yip-Schneider
@cy
Michele T Yip-Schneider
@da
P106
P1153
6603594207
P1412
P21
P31
P3835
michele-yip-schneider
P496
0000-0001-7569-7971